Your browser is no longer supported. Please, upgrade your browser.
Settings
HOWL [NASD]
Werewolf Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own12.92% Shs Outstand27.19M Perf Week-8.38%
Market Cap422.14M Forward P/E- EPS next Y-2.03 Insider Trans9.74% Shs Float24.02M Perf Month-3.10%
Income- PEG- EPS next Q-0.44 Inst Own78.80% Short Float2.74% Perf Quarter-15.32%
Sales- P/S- EPS this Y-54.80% Inst Trans-3.25% Short Ratio25.18 Perf Half Y0.67%
Book/sh6.23 P/B2.40 EPS next Y64.70% ROA- Target Price26.20 Perf Year-
Cash/sh6.05 P/C2.48 EPS next 5Y- ROE- 52W Range11.23 - 23.99 Perf YTD-6.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.77% Beta-
Dividend %- Quick Ratio22.40 Sales past 5Y- Gross Margin- 52W Low32.95% ATR0.94
Employees28 Current Ratio22.40 Sales Q/Q- Oper. Margin- RSI (14)36.33 Volatility9.63% 5.73%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume6.48 Prev Close14.98
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume26.15K Price14.93
Recom1.50 SMA20-5.60% SMA50-8.75% SMA200-5.62% Volume87,730 Change-0.33%
Sep-10-21Initiated BofA Securities Buy $26
May-25-21Initiated SVB Leerink Outperform $29
May-25-21Initiated Jefferies Buy $22
May-25-21Initiated H.C. Wainwright Buy $32
May-25-21Initiated Evercore ISI Outperform $23
Nov-10-21 07:00AM  
Nov-08-21 08:03AM  
Oct-28-21 04:01PM  
Oct-27-21 07:30AM  
Sep-14-21 08:00AM  
Sep-08-21 08:00AM  
Aug-19-21 10:57AM  
Aug-18-21 07:30AM  
Aug-12-21 07:00AM  
Jul-30-21 05:03AM  
Jun-24-21 07:00AM  
Jun-18-21 09:16PM  
Jun-15-21 07:00AM  
Jun-10-21 07:00AM  
May-27-21 07:30AM  
May-21-21 07:41PM  
Apr-30-21 04:44PM  
12:00PM  
Apr-29-21 09:19PM  
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorJun 16Buy13.379,285124,1404,291,881Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 15Buy12.957,958103,0564,282,596Jun 16 04:58 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 14Buy12.75306,0553,902,2014,274,638Jun 16 04:58 PM
Sphera Global Healthcare Manag10% OwnerMay 04Buy16.00475,0007,600,000787,997May 04 01:21 PM
Longwood Fund III GP, LLC10% OwnerMay 04Buy16.00250,0004,000,0001,677,082May 04 04:30 PM
Arkin Bio Ventures 2 L.P.10% OwnerMay 04Buy16.00400,0006,400,0002,046,634May 04 04:31 PM
Asanuma SakaeDirectorMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Taiho Ventures LLC10% OwnerMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Lazarus AlonDirectorMay 04Buy16.00400,0006,400,0002,046,634May 04 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 04Buy16.001,715,00027,440,0003,524,758May 06 04:31 PM
MPM BioVentures 2014, L.P.10% OwnerMay 04Buy16.00125,7592,012,1443,187,998May 06 04:20 PM
GADICKE ANSBERT10% OwnerMay 04Buy16.00245,0003,920,0006,672,183May 06 04:19 PM
EVNIN LUKEDirectorMay 04Buy16.00150,7992,412,7844,284,172May 06 04:19 PM
Flynn James EPossible Member of 10% GroupMay 04Buy16.00800,00012,800,0002,552,787May 04 12:34 PM